SHOP BEST SELLERS
Shop our best selling products
Type: Performance Supplements
Protein Powder
Type: Performance Supplements
Electrolytes - Stick Packs
Type: Performance Supplements
Electrolytes
Type: Performance Supplements
Creatine Monohydrate
Type: Core Supplements
Source Magnesium
Type: Core Supplements
Vitamin D3 & K2
Type: Body Essentials
Raw Elements Shampoo
Type: Body Essentials
Raw Elements Conditioner
Type: Body Essentials
Raw Elements Tallow Soap (Lemongrass)
Type: Performance Supplements
Raw Honey
Type: Body Essentials
Raw Tallow Sun Balm
★★★★★ 1,000+ 5 Star Reviews
Pure ingredients
Raw ingredients. Ancient wisdom. Modern results. Every product contains only what nature intended:
- Grass-fed tallow rich in bioavailable nutrients
- Raw honey and adaptogenic herbs in their purest form
- Regeneratively sourced proteins, never denatured
- Zero synthetic additives or lab-made fillers
Small-batch wellness our ancestors would recognize. Because when you honor nature's integrity, your body knows the difference.
Purely Natural, Perfectly You
Let customers speak for us
Taste great and mixes well into a smoothie
It's a bit more liquidity than the usual body wash but overall its nice. Smells good and makes my body soft.
It's a bit thick but its still nice and it smells really good. I feel as though it cleans my scalp well
It's a nice consistency, makes my hair really shiny and moisturized and smells amazing.
Love it
The best protein powder I have ever tried
The best electrolytes I ever tried
It's nice and smells really good.
used on baby
Great product
Best Shampoo ever made! Makes my hair lush and thicker! This shampoo is top notch and a must have!
Love the smell
Always looking for a clean alternative for supplements. Great Taste. Excited to try other flavors.
I’ve used the shampoo & conditioner 3 times now and my hair is so soft, manageable and clean! Lovin’ it
Started using this product recently and so far I love it. Everything comes as listed, smells great and I feel like I’m washing my hair with a clean product. Can’t beat it.
Why PÜRISHH?
Pure Ingredients
Handpicked and ethically sourced from trusted, natural farms.
Effective Results
Each product is designed to protect, nourish, and enhance your skin’s natural balance.
Holistic Wellness
Embrace a balanced lifestyle with supplements and creams that work in harmony with your body.
Frequently Asked Question
What makes PÜRISHH products different from conventional supplements or skincare?
What makes PÜRISHH products different from conventional supplements or skincare?
Our mission is to return to the raw, unprocessed power of nature. Every product is formulated with 100 % natural ingredients and no synthetic preservatives, fillers, or dyes. For example, the Raw Honey Butter contains whipped Wagyu beef tallow, cold‑pressed olive and coconut oils, mango butter, raw honey and beeswax – it moisturizes deeply and can even replace conventional lotion. The Raw Tallow Sunbalm uses grass‑fed tallow, non‑nano zinc oxide and organic oils to provide mineral sun protection while nourishing the skin. Our Protein Powder combines grass‑fed whey and hydrolyzed collagen with organic superfoods to deliver 26 g of easily digestible protein with zero added sugar. Across their range, Purishh keeps ingredient lists short and transparent, using only what is necessary to support health and well‑being.
Are PÜRISHH’s ingredients ethically and sustainably sourced?
Are PÜRISHH’s ingredients ethically and sustainably sourced?
Yes. The founders emphasize sustainable sourcing and ethical treatment of animals and land. Tallow for the skincare range is hand‑sourced from 100 % grass‑fed, Wagyu, halal cattle in New Zealand, ensuring humane slaughter and optimal nutrient quality. Olive and coconut oils are single‑origin, cold‑pressed. The whey in Purishh protein powder comes from grass‑fed cows raised without hormones or antibiotics, and the collagen is hydrolyzed for better absorption. These practices mean customers receive products that are both pure and sustainable.
Why does PÜRISHH use beef tallow in its skincare products?
Why does PÜRISHH use beef tallow in its skincare products?
Grass‑fed beef tallow is biocompatible with human skin; its fatty‑acid profile closely resembles natural sebum, so it’s absorbed efficiently. Properly rendered tallow is a vitamin powerhouse, naturally supplying vitamins A, D, E, and K that support cell turnover, immune function, and antioxidant protection. Tallow also contains oleic, stearic and palmitic acids that strengthen the skin’s barrier, calm inflammation and maintain moisture. Grass‑fed tallow offers a high concentration of conjugated linoleic acid (CLA), an anti‑inflammatory fatty acid. These nutrients collectively help Purishh’s Raw Honey Butter and Raw Tallow Sunbalm to moisturize, nourish and protect the skin without clogging pores or causing irritation.
How is PÜRISHH protein powder different, and why is it easy to digest?
How is PÜRISHH protein powder different, and why is it easy to digest?
Many conventional protein powders use cheap sources and add artificial thickeners or sweeteners that cause bloating and digestive discomfort. Purishh starts with grass‑fed whey processed via cold‑filtration, which preserves natural enzymes and bioactive peptides that aid digestion. It also adds hydrolyzed bovine collagen to support joints, skin and gut health. The powder uses organic monk fruit for sweetness and contains no carrageenan, gums, sucralose or artificial preservatives, so it mixes smoothly and is gentle on the stomach. Each serving provides 26 g of complete protein with only 1 g of fat and zero sugar, making it suitable for keto, gluten‑free and non‑GMO diets.
What are PÜRISHH Electrolytes, and how do they support hydration?
What are PÜRISHH Electrolytes, and how do they support hydration?
PÜRISHH’s Electrolytes formula offers clean hydration without the artificial colors and preservatives found in many sports drinks. Each serving includes over 800 mg of unrefined Himalayan salt, providing sodium and trace minerals, plus magnesium malate and potassium chloride. Organic fruit powders (raspberry or lemon‑lime) and monk fruit sweetener give a natural flavor without sugar. The formula helps replenish electrolytes lost through exercise, supports muscle function, and is keto‑friendly.
What is Raw Shilajit, and how should it be used?
What is Raw Shilajit, and how should it be used?
Raw Shilajit is a resin harvested from high‑altitude Himalayan rocks. It forms from decomposed plant material and is rich in minerals and fulvic acid. Traditionally used as an adaptogen, Shilajit helps boost energy, improve stamina and support overall health. Purishh provides 100 % pure Himalayan shilajit. Users typically dissolve a pea‑sized amount in warm water, tea or milk. Due to its potent minerals, start with a small dose and consult a healthcare professional if you have existing medical conditions.
What is the Ishh Leaky Gut Protocol?
What is the Ishh Leaky Gut Protocol?
The Ishh Leaky Gut Protocol is a step‑by‑step program designed to help restore gut health naturally. It includes dietary recommendations, lifestyle tips and natural supplements to support the intestinal lining. The protocol focuses on removing irritants, replenishing beneficial bacteria and repairing the gut barrier. It is not a medical treatment, so customers with chronic digestive issues should consult a healthcare professional before starting.
How should I store PÜRISHH products?
How should I store PÜRISHH products?
Store supplements and protein powders in a cool, dry place away from direct sunlight. Skincare products like Raw Honey Butter and Raw Tallow Sunbalm are natural and free from artificial stabilizers; keeping them at room temperature helps maintain texture. If you live in a hot climate, refrigerating tallow‑based balms can prevent melting. Always use clean hands or a spatula to avoid introducing bacteria.
When will my order ship, and how long will delivery take?
When will my order ship, and how long will delivery take?
We ask customers to allow 2–3 business days for processing and production before an order ships. Once dispatched, average transit times are 7–10 business days; however, natural disasters, holidays and weather can cause delays. Free standard shipping is offered on orders over US$150 (or equivalent), and shipping costs for smaller orders are calculated at checkout. PÜRISHH cannot guarantee exact delivery dates because delivery is ultimately the responsibility of the shipping carrier.
Can I subscribe and save on regular purchases?
Can I subscribe and save on regular purchases?
Yes. We offer a subscription program for most of our products. Subscribe and save up to 30 % OFF your first delivery. You can choose delivery intervals (e.g., monthly). Subscriptions auto‑renew, but you may skip or cancel at any time through your account.
Are PÜRISHH products allergen‑free or suitable for special diets?
Are PÜRISHH products allergen‑free or suitable for special diets?
PÜRISHH formulates products without common synthetic additives, but some items may contain potential allergens. The protein powder contains whey (a dairy product) and collagen derived from bovine sources; it is unsuitable for vegans or those with dairy allergies. The Electrolytes formula is gluten‑free, sugar‑free and keto‑friendly. Always review ingredient lists carefully and consult your healthcare provider if you have specific allergies or dietary restrictions.
Where are PÜRISHH products made?
Where are PÜRISHH products made?
PÜRISHH sources ingredients globally, such as New Zealand Wagyu tallow and Himalayan shilajit, but manufactures products in small batches under rigorous quality control. By keeping production small and hands‑on, PÜRISHH can maintain freshness and ensure every batch meets the highest standards.
PÜR Insights
Brain Fog in Midlife: Separating Mechanism from Marketing
Brain Fog in Midlife: Separating Mechanism from Marketing Walking into a room and forgetting why. Losing a word you use every day. Rereading the same paragraph three times. Women describe this in almost identical terms during their 40s and early 50s, and for a long time the standard response was some version of "it's stress" or "it's just getting older." That response turned out to be partly wrong. There is now good longitudinal evidence that something measurable happens to cognition during the menopause transition. There is also good evidence about what that something is, how large it is, and how long it lasts. That evidence is considerably more reassuring than the worry it tends to produce, and considerably less useful to supplement marketing than the marketing would like. This post covers what the research actually measured, what it points to as contributing factors, and how the most common "brain fog" products hold up against it. "Brain fog" is a description, not a diagnosis Start with the term itself. Brain fog is not a medical diagnosis. It has no diagnostic criteria, no agreed definition, and no test. Researchers studying it generally use the phrase subjective cognitive complaints, meaning what people report experiencing, and they measure it separately from objective cognitive performance, meaning what people actually score on standardized tests. That distinction matters more than it sounds. A subjective complaint is real. It describes a genuine experience. But it doesn't tell you which mechanism is behind it, and very different causes can produce the same feeling. Poor sleep produces it. Anxiety produces it. Depression produces it. So can thyroid problems, anemia, certain medications, and plain overload. A product sold "for brain fog" is sold for a feeling, which means it can be marketed to almost anyone without claiming to treat anything specific. What the best longitudinal data found The most important research on this comes from the Study of Women's Health Across the Nation, known as SWAN, a multicenter, multiethnic, community-based study that has followed a large cohort of US women through the menopause transition. The key analysis was published by Gail Greendale and colleagues in Neurology in 2009, volume 72, pages 1850 to 1857. They followed 2,362 women over four years and repeatedly tested three cognitive domains: processing speed using the Symbol Digit Modalities Test, verbal memory using the East Boston Memory Test, and working memory using Digit Span Backward. When cognitive testing began, the women's mean age was 50. The design is worth understanding, because the finding depends on it. When people take the same cognitive test several times, they normally get better at it. This practice effect is expected in midlife and shows up reliably in healthy adults. Here is what SWAN found. Women who were premenopausal, early perimenopausal, or postmenopausal improved with repeated administration of the processing speed test, with a p-value at or below 0.0008. Women in late perimenopause did not improve, with a p-value of 0.2. Verbal memory showed a similar perimenopausal decrement. And after the transition, improvement rebounded to premenopausal levels. The authors concluded that perimenopause was associated with a decrement in cognitive performance, characterized by women not learning as well as they had before, and that these difficulties may be time-limited. The detail that changes how this should feel Read that finding carefully, because the popular version of it is not quite what the study showed. A later progress report from the SWAN investigators, led by El Khoudary and published in 2019, spelled out the distinction directly. The perimenopause effect was subtle. It showed up as the absence of a learning effect, not as a drop. As the report puts it, even in perimenopause, test scores did not drop. They simply did not improve during that stage. Not getting better and getting worse are different things. What was measured during the transition was a temporary loss of the usual improvement with practice, and it recovered afterward. The same report noted that approximately 60 percent of midlife women report problems with memory during the transition. So both facts hold at once. The complaint is common and real. The measured change is modest and appears to be temporary. Researchers reviewing this literature have described these changes as occurring without indicating neurodegenerative disease. If you're in your 40s and worried that losing words means something is going badly wrong, this is the most relevant finding available, and it is a reassuring one. Not every study agrees, and that's worth knowing It would be easy to present SWAN as the final word. It isn't, and the literature is honest about that. In a 2010 follow-up paper in the American Journal of Epidemiology, Greendale and colleagues summarized the small body of longitudinal research available at the time. Two of three published longitudinal studies corroborated women's perceptions. The Kinmen Women-Health Investigation found a perimenopause-related deficit in verbal memory. A two-year substudy at SWAN's Chicago site found that processing speed and working memory were unaffected by the transition. The larger four-year analysis across all seven SWAN sites found the transient decrement described above. A 2023 structured review in Frontiers in Aging Neuroscience noted that there has been insufficient research to determine whether these effects are time-limited, and suggested that studies with more repeated assessments across a wider age span would help settle the question. The fairest summary is that the best evidence points toward a modest, domain-specific, probably temporary effect, with some disagreement between studies about exactly which domains are affected. The mechanism question: is it just hormones? The obvious explanation is estrogen. Estrogen acts on the brain, including regions involved in memory, and its levels fluctuate and then decline across the transition. That is a plausible mechanism, and it is where most marketing starts. The evidence complicates it. An earlier cross-sectional SWAN analysis by Luetters and colleagues, published in the Journal of Women's Health in 2007, volume 16, pages 331 to 344, examined whether menopause stage and circulating levels of estradiol and follicle-stimulating hormone were related to cognitive performance. The title states the result: they were not. That was a cross-sectional analysis, so it can't rule out effects that show up over time within individuals. But it does mean the simple story, where a lower estrogen number on a blood test equals worse memory, isn't supported by that data. The transition is clearly involved in some way, since the effect appears during perimenopause and resolves after it. Exactly how is not settled. What SWAN points to as contributors This is the part of the research that usually gets skipped, and it is arguably the most useful. SWAN's own published guidance on memory and cognition notes that sleep and mood problems increase during the menopause transition. It states plainly that lack of sleep is linked to poor memory and difficulty focusing, and that depression and anxiety impair effort and performance on cognitive testing. SWAN women with depressive symptoms performed less well on tests of processing speed. The 2019 progress report found that among women who had no anxiety before the transition, anxiety symptoms became more likely across it, rising from early to late perimenopause and then declining after menopause. It also found that perceived health below very good, and at least one upsetting life event in the past year, carried greater risk of anxiety symptoms than menopause stage did. Life circumstances mattered at least as much as hormonal stage. Put those together and a practical picture emerges. Several things that impair thinking become more common during exactly this window. Sleep gets disrupted, including by night sweats. Anxiety becomes more likely. Mood shifts. Each of these independently makes it harder to concentrate and remember. Whether they fully explain the cognitive effect or sit alongside a direct hormonal one is still being worked out. But they are real, they are measurable, and unlike estrogen levels, many of them can be addressed directly. Separating the transition from aging There is a second thing happening in midlife, and it's easy to confuse with the first. SWAN has also tracked cognitive aging beyond the transition. According to SWAN's published summaries, age-related declines appear in processing speed in the early 50s, in memory around age 58, and in working memory around age 61. The transition-related memory changes appear to be reversible, while persistent declines only become apparent well after menopause. The rate of that longer-term decline isn't the same for everyone. SWAN reports that financial hardship was consistently associated with accelerated cognitive decline. Diabetes, elevated fasting glucose, central obesity, hypertension, and poor heart health were associated with the rate of decline in processing speed. That list is notable for what's on it. The factors associated with how quickly thinking slows with age are largely cardiometabolic and social, not nutritional gaps that a capsule would close. SWAN is careful here too. Its guidance notes that controlling blood pressure, glucose, and weight is important for overall health, and that whether controlling them also lessens cognitive decline is being tested in ongoing clinical trials. That is the right level of confidence, and it's a higher standard than most brain supplements hold themselves to. Where marketing enters The gap between a common, distressing, poorly defined complaint and a modest, temporary, multi-factor explanation is exactly the space supplement marketing fills. So it's worth checking the most common claims against the most rigorous evidence available. Ginkgo biloba. Ginkgo is the most studied memory supplement in the world, and it has been tested in the largest trial of its kind. The Ginkgo Evaluation of Memory study, co-funded by several arms of the US National Institutes of Health, followed 3,069 community-dwelling older adults with normal cognition or mild cognitive impairment. Participants took 120 milligrams of ginkgo extract twice daily or a placebo, across four clinical sites over eight years. The primary results, published by DeKosky and colleagues in JAMA in 2008, volume 300, pages 2253 to 2262, found ginkgo did not reduce the incidence of dementia or Alzheimer's disease. A secondary analysis by Snitz and colleagues in JAMA in 2009, volume 302, pages 2663 to 2670, followed participants for a median of 6.1 years and found ginkgo did not slow the rate of cognitive decline. This trial studied older adults, not women in midlife, which limits how directly it applies. But it is the most rigorous test ever run on the most heavily marketed memory supplement, and it found nothing. If ginkgo had a meaningful effect on memory, a trial of that size and length was well placed to detect it. Creatine. Creatine has become a popular brain fog recommendation, especially for midlife women, and we've covered the evidence in detail elsewhere. The short version: the European Food Safety Authority's expert panel reviewed 21 human intervention studies in 2024 and concluded that a cause-and-effect relationship between creatine supplementation and improved cognitive function had not been established. The mechanism is plausible. The trial evidence isn't there yet. Magnesium. Magnesium, particularly the L-threonate form, is marketed for menopausal cognitive symptoms. The researchers running a clinical trial currently investigating magnesium L-threonate for menopausal symptoms state in their own trial registration that research on its effect on overall menopausal symptoms is rare. Products are being sold on a question the investigators themselves describe as largely open. We sell creatine and a magnesium complex that includes L-threonate. None of the above changes the reasons they can be worth taking, which we've written about separately. But neither is an established treatment for brain fog, and we're not going to describe them that way. Why mechanism isn't enough Every product above has a plausible mechanism. Ginkgo affects blood flow. Creatine supports cellular energy in the brain. Magnesium participates in nerve signaling. Estrogen acts on memory regions. All of this is real biology. In each case, the step from "this is involved in the relevant biology" to "taking this improves the thing people actually care about" either failed when it was tested or hasn't been tested well. That step is the entire difference between mechanism and marketing. A mechanism tells you something might work. Only a controlled trial tells you whether it does. In this area, the trials that exist have mostly been disappointing, and the complaint being targeted is common enough and vague enough that a product can sell well without ever closing that gap. What's worth doing instead Based on what SWAN and related research actually identify, the more defensible priorities are fairly unglamorous. Treat sleep as a cognitive issue, not just a comfort issue. SWAN's guidance links lack of sleep directly to poor memory and trouble focusing. If night sweats or insomnia are breaking up your nights, that's worth raising with a clinician, and it may do more for your thinking than any supplement. Take mood and anxiety seriously. Depressive symptoms were associated with slower processing speed in SWAN, and anxiety becomes more likely across the transition. Both are treatable, and treating them is likely to help cognition along the way. Keep an eye on the cardiometabolic basics that SWAN associates with long-term decline, including blood pressure, glucose, and central weight, while understanding that the trials testing whether controlling them protects cognition are still running. Hormone therapy is a separate medical decision with its own body of evidence. It belongs in a conversation with a clinician, not in a supplement brand's blog, so we're leaving it out here. And watch for the one pattern SWAN specifically flags. Its guidance advises that if memory changes come on suddenly, they should be reported to a primary care provider. Gradual, on-and-off word-finding trouble in your late 40s fits the research pattern described above. A sudden change doesn't, and deserves a proper evaluation. The honest summary Brain fog in midlife is a real and common experience. Around 60 percent of women report memory problems during the menopause transition, according to SWAN. The best longitudinal evidence, SWAN's four-year study of 2,362 women, found a modest effect. During late perimenopause, women didn't show the usual improvement with repeated testing, and that improvement came back after menopause. Scores didn't fall. They stopped rising, temporarily. Not every study agrees on which cognitive domains are affected, and researchers note that more work is needed to confirm the effect is time-limited. The mechanism isn't as simple as circulating estrogen, which SWAN found was not related to cognitive performance in a cross-sectional analysis. The factors SWAN does identify, including disrupted sleep, anxiety, depressive symptoms, and life stress, are common during this window and can be addressed. Against that background, the most marketed products don't hold up well. The largest trial of ginkgo found no effect on dementia or cognitive decline. EFSA found cause and effect not established for creatine and cognition. Researchers studying magnesium L-threonate for menopausal symptoms describe the existing research as rare. That's a less exciting message than most brain fog content offers, and a more useful one. The measured change is smaller than the fear around it. Much of what drives the experience is sleep, mood, and stress. And right now the evidence supports addressing those directly more than it supports buying anything, including from us.
Learn more
Bone Density After Menopause: Where D3, K2, and Protein Fit
Bone Density After Menopause: Where D3, K2, and Protein Fit Three nutrients dominate the conversation about bone health after menopause. All three have more complicated evidence than the marketing suggests, and the complications run in different directions. One has been substantially undercut by large randomized trials and now carries formal recommendations against its routine use for this purpose. One has genuinely mixed trial results. And one spent decades being blamed for harming bone before the research reversed, and now has modestly positive support. This post covers what the evidence actually shows for each, where the honest limits sit, and what the research consistently identifies as mattering more than any of them. What happens to bone after menopause Bone is living tissue in continuous turnover, with osteoclasts breaking down old bone and osteoblasts building new bone. Estrogen plays a regulatory role in keeping that cycle balanced. When estrogen declines through the menopausal transition, resorption begins outpacing formation, and bone density falls. The result is an accelerated loss that is specific to this period rather than a general feature of aging. It is also the reason bone health becomes a more prominent concern for women in midlife than for men of the same age. Osteoporosis itself is a clinical diagnosis with defined criteria and established medical treatments. Nothing in this post addresses treatment, and anyone with diagnosed osteoporosis or osteopenia should be working with a physician rather than substituting nutritional strategies for medical care. What follows is about what nutrition contributes, which is a narrower question. Vitamin D: what the large trials found This is where the evidence has shifted most dramatically, and where the gap between current guidance and popular assumption is widest. The VITAL trial is the central piece of evidence. Published by LeBoff and colleagues in the New England Journal of Medicine in 2022, volume 387, issue 4, pages 299 to 309, it was an ancillary study of a two-by-two factorial randomized controlled trial testing supplemental vitamin D3 at 2,000 IU per day against placebo. The ancillary study included 25,871 participants with a mean age of 67, of whom 51 percent were women, drawn from all 50 US states. Participants were men aged 50 and older and women aged 55 and older, and were not recruited on the basis of vitamin D deficiency, low bone mass, or osteoporosis. The primary endpoints were incident total, nonvertebral, and hip fractures, reported on annual questionnaires and adjudicated by centralized medical record review. The finding: vitamin D3 supplementation did not result in a significantly lower risk of fractures than placebo. One detail is worth emphasizing because it preempts the most common objection. The absence of benefit persisted even among participants with lower baseline 25-hydroxyvitamin D concentrations, below 20 nanograms per millilitre. The null result was not simply an artifact of studying an already-replete population. These findings were corroborated by the DO-HEALTH study in Europe and the D-Health trial in Australia, both of which similarly found no significant reduction in fracture risk among vitamin D-replete older adults. The accompanying editorial by Cummings and Rosen, published in the same issue, was titled "VITAL findings: A decisive verdict on vitamin D supplementation." What the guidelines now say The regulatory and professional response has followed the evidence, and it is more direct than most people realize. The US Preventive Services Task Force, in its 2024 draft recommendation, issued a grade D statement against vitamin D supplementation for the primary prevention of fractures and falls in community-dwelling adults. A grade D recommendation means the task force recommends against the service, having concluded there is no net benefit or that harms outweigh benefits. The stated reasoning cited potential harms including nephrolithiasis, combined with the absence of net benefit observed in trials such as VITAL, in a largely vitamin D-sufficient population. The 2024 Endocrine Society Clinical Practice Guideline similarly advises against empiric vitamin D supplementation in healthy adults younger than 75, and discourages routine screening of serum 25-hydroxyvitamin D levels. Both bodies maintain that supplementation remains appropriate for specific subgroups, including adults aged 75 and older, pregnant individuals, and those at elevated metabolic risk such as people with prediabetes. The scope of these recommendations matters and should not be overstated in either direction. They address primary prevention in community-dwelling adults without known osteoporosis or established deficiency. They do not address people with diagnosed deficiency, diagnosed osteoporosis, or the specific subgroups named above. Vitamin D remains genuinely necessary for calcium absorption, and correcting a genuine deficiency remains a legitimate clinical intervention. What has changed is the case for taking vitamin D as a fracture-prevention measure if you are a generally healthy adult without deficiency. That case has weakened substantially. Vitamin K2: mixed, as covered previously We have written about vitamin K2 and bone in detail elsewhere, including the trials that disagree, so this will be brief. The headline evidence is the Knapen trial, published in Osteoporosis International in 2013, a three-year randomized controlled trial in 244 postmenopausal women aged 55 to 65 taking 180 micrograms of MK-7 daily. It found significantly decreased age-related decline in bone mineral density at the lumbar spine and femoral neck, though not at the total hip, and reduced vertebral height loss. It sits alongside other rigorous trials that found no significant benefit, including a 2010 trial by Emaus and colleagues in 334 Norwegian women using 360 micrograms of MK-7 for one year, a 2020 three-year trial in 142 postmenopausal women with osteopenia using 375 micrograms daily that found no difference from placebo at any measured site, and work by Binkley and colleagues that confirmed vitamin K reduced undercarboxylated osteocalcin as expected while producing no detectable change in bone turnover, density, or geometry. The mechanism, involving K2-dependent carboxylation of osteocalcin, is well established at the biochemical level. Whether that translates into measurable bone outcomes remains genuinely contested, with well-designed trials reaching opposing conclusions. Protein: the reversal worth knowing about Protein has the most interesting history of the three, because the prevailing view was wrong for decades in a specific and identifiable way. The acid-ash hypothesis held that dietary protein, particularly animal protein, generates an acid load that the body neutralizes by drawing calcium from bone, thereby causing bone loss. It was widely accepted, widely taught, and drove recommendations to limit protein intake for bone health. A series of analyses by Fenton and colleagues systematically dismantled it. Their 2009 meta-analysis in the Journal of Bone and Mineral Research, volume 24, pages 1835 to 1840, examined the effect of the acid-ash hypothesis on calcium balance. Their 2011 paper in Nutrition Journal, volume 10, article 41, conducted a causal assessment of dietary acid load and bone disease applying Hill's epidemiological criteria for causality. The hypothesis did not survive that scrutiny, and a subsequent meta-analysis found no evidence for a protective effect of an alkaline diet on bone health. What replaced it is a modestly positive picture, though one with real internal tension worth reporting honestly. An expert consensus paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases and by the International Osteoporosis Foundation, published in Osteoporosis International in 2018, concluded that in older people with osteoporosis, higher protein intake at or above 0.8 grams per kilogram of body weight per day is associated with higher bone mineral density, a slower rate of bone loss, and reduced risk of hip fracture, provided calcium intake is adequate. The Health, Aging, and Body Composition Study found that higher protein intake was associated with lower vertebral fracture risk, with the upper protein tertile, averaging 1.1 grams per kilogram per day, showing 1.8 to 6.0 percent higher mean baseline bone mineral density. The authors concluded that the lower end of the acceptable macronutrient distribution range and the 0.8 gram per kilogram RDA may be suboptimal for bone mineral density preservation in older adults. A meta-analysis of cross-sectional studies attributed a 2 to 4 percent increase in bone mineral density to protein intake above the RDA. Here is the tension. A systematic review and meta-analysis conducted for the National Osteoporosis Foundation and published in the American Journal of Clinical Nutrition pooled six randomized controlled trials and found no difference between higher and lower protein intake on femoral neck bone mineral density, with a pooled mean percentage change of negative 0.14 percent, a 95 percent confidence interval of negative 0.60 to 0.32, and zero statistical heterogeneity. So the observational and cohort evidence associates higher protein intake with better bone outcomes, particularly fracture risk, while the randomized trial evidence on bone mineral density specifically shows no difference. That pattern can reflect several things: that protein affects fracture risk through pathways other than density, such as muscle mass and fall prevention; that observational associations are confounded by overall dietary quality; or that the RCTs were too short to detect changes in a slow-moving outcome. The honest reading: protein is not harmful to bone, which was the older belief and was wrong. The evidence that higher intake actively improves bone density in randomized trials is absent. The evidence associating it with lower fracture risk is real but observational. What the research consistently identifies as mattering more Across this literature, one intervention appears more consistently than any nutrient, and it is not a supplement. Weight-bearing and resistance exercise applies mechanical load to bone, and bone responds to mechanical load by remodelling. This is the same principle underlying why astronauts lose bone density in microgravity and why the loading history of a limb affects its density. It is a direct stimulus rather than a supporting input. There is also a compounding factor specific to fractures rather than density. Most osteoporotic fractures occur as a result of falls. Muscle strength, balance, and reaction time determine fall risk, and all three respond to resistance and balance training. A person with stronger legs and better balance falls less often, and fracture risk is a function of both bone fragility and the frequency of the events that stress it. This is why interventions combining resistance training with nutritional support consistently outperform nutritional support alone in the broader literature on musculoskeletal outcomes in older adults, a pattern we have examined in detail elsewhere. The honest hierarchy Putting this together for bone health after menopause specifically. Weight-bearing and resistance exercise has the most direct mechanism and the strongest case, both for bone loading and for reducing the falls that convert low bone density into actual fractures. Adequate calcium intake remains a foundational requirement, and the ESCEO and IOF protein consensus explicitly conditions its findings on adequate calcium. Adequate protein is supportive and no longer suspect. The old acid-ash concern has been overturned. Higher intake associates with lower fracture risk in cohort data, while randomized trials show no bone density difference. The recommendations at or above 0.8 grams per kilogram per day are reasonable, and overlap with the intake ranges recommended for muscle preservation. Vitamin D remains necessary for calcium absorption, and correcting a genuine deficiency remains legitimate. Taking it as a fracture-prevention measure without deficiency is not supported by VITAL, DO-HEALTH, or D-Health, and both the USPSTF and the Endocrine Society have issued recommendations reflecting that. Vitamin K2 has a well-established biochemical mechanism and genuinely contested trial results, with one three-year trial finding site-specific benefits and several equally rigorous trials finding none. What this means for us We sell a vitamin D3 and K2 product, and the evidence above complicates the case for it more than it supports it. Stating that plainly is the only defensible option. For D3, the honest position is that the fracture-prevention rationale does not hold up for generally healthy adults without deficiency, based on trials involving tens of thousands of participants and reflected in current guidance from two major bodies. Vitamin D still has a real physiological role in calcium absorption, deficiency is still worth correcting, and specific populations still warrant supplementation. But if the reason you are taking D3 is to prevent fractures and you are not deficient, the large randomized trials do not support that expectation. For K2, the position we have held across previous posts stands: promising mechanism, genuinely mixed trial results, not established. Anyone wanting to know their actual vitamin D status can have it measured, though it is worth noting that the Endocrine Society's 2024 guidance specifically discourages routine screening in healthy adults under 75, which is itself a signal about how the field now views population-wide vitamin D management. The honest summary Bone loss accelerates after menopause because estrogen's regulatory role in bone turnover diminishes. That is real and worth taking seriously. Vitamin D3 supplementation did not reduce fracture risk in VITAL, a trial of 25,871 participants, and the null result held even in those with lower baseline vitamin D levels. DO-HEALTH and D-Health corroborated it. The USPSTF issued a grade D recommendation against supplementation for primary fracture prevention in community-dwelling adults in 2024, and the Endocrine Society advises against empiric supplementation in healthy adults under 75. Vitamin K2 has a solid biochemical mechanism and contradictory trial results, with rigorous studies on both sides. Protein is the most improved story: the decades-long belief that it harms bone was overturned by Fenton and colleagues, and current expert consensus associates intake at or above 0.8 grams per kilogram with better bone outcomes, though randomized trials show no bone density difference and the positive findings are observational. And exercise, specifically weight-bearing and resistance training, remains the intervention with the most direct mechanism and the clearest role, both in loading bone and in reducing the falls that turn low density into fractures. That is a less supplement-friendly conclusion than most content on this topic reaches. It is what the trials found.
Learn more
Magnesium and Hormonal Change: What the Evidence Actually Supports
Magnesium and Hormonal Change: What the Evidence Actually Supports Magnesium is marketed for essentially every hormone-related complaint a woman might have: premenstrual symptoms, perimenopausal mood changes, hot flashes, cortisol regulation, thyroid function. The mechanistic reasoning offered is usually plausible, and the confidence of the claims is usually high. The clinical evidence does not match that confidence. In several of these areas it points the other way, and in at least one case the most frequently cited supporting study has a methodological problem that explains a great deal about why the result looked as good as it did. This post separates the mechanism from the outcomes, examines what the trials actually found, and identifies the one area where magnesium's evidence in this context is genuinely reasonable. It is a narrower conclusion than most content on this topic offers. The mechanism is real, and mechanism is not evidence Magnesium participates in a large number of physiological processes relevant to hormonal function. It influences GABA signalling, the brain's primary inhibitory neurotransmitter system. It plays a role in the regulation of the stress response, including pathways involving cortisol. It is involved in processes touching serotonin, norepinephrine, and thyroid-stimulating hormone. It is required for the enzymatic activity underlying a broad range of metabolic functions. All of that is accurate and none of it is in dispute. What it establishes is that magnesium could plausibly influence hormone-related symptoms. It does not establish that supplementing magnesium does influence them in a measurable, clinically meaningful way. That second question requires clinical trials, and this is precisely where the gap between marketing and evidence opens up. The distinction matters because mechanistic plausibility is abundant in nutrition science and frequently fails to translate. A compound can participate in a relevant pathway and still produce no detectable change in the outcome people actually care about, either because the pathway was not the limiting factor, or because supplementation does not shift it far enough to matter. Premenstrual symptoms: what the reviews concluded Premenstrual syndrome affects roughly 48 percent of women of reproductive age worldwide, and magnesium is one of the most commonly recommended nutritional interventions for it. The evidence base is worth examining directly. A systematic review of randomized controlled trials examining nutritional interventions for the psychological symptoms of premenstrual syndrome, published in Nutrition Reviews in 2025, volume 83, issue 2, reached a specific conclusion about magnesium. The review found insufficient evidence to support the effects of vitamin B1, vitamin D, whole-grain carbohydrates, soy isoflavones, dietary fatty acids, magnesium, multivitamin supplementation, or PMS-specific diets on psychological premenstrual symptoms. Magnesium appears in that list by name. This is a systematic review of randomized controlled trials concluding that the evidence for magnesium in this application is insufficient. There is one finding worth reporting alongside it, because it is more nuanced than a flat negative. The same review describes a randomized crossover study of 44 British women with PMS in which a daily combination of 200 milligrams of magnesium and 50 milligrams of vitamin B6, taken for one month, produced a significant decrease in anxiety-related symptoms including nervous tension, mood swings, irritability, and anxiety, compared with single nutrients or placebo, with a p-value of 0.04. Read that carefully. The combination outperformed single nutrients. Which means magnesium on its own, tested within the same study, did not produce the effect. The review's overall assessment of combined nutrient and multivitamin supplements for psychological PMS symptoms was that the evidence remains limited. A separate systematic review and meta-analysis of observational studies examining the association between serum magnesium levels and premenstrual syndrome, covering 13 studies, described the findings across the literature as inconclusive. For context on what better evidence in this area looks like: a systematic review and meta-analysis of randomized controlled trials examining exercise for premenstrual syndrome found reduced global PMS symptom scores with a standardized mean difference of negative 1.08 and a 95 percent confidence interval of negative 1.88 to negative 0.29. Even that result came with substantial heterogeneity at 87 percent and with 87 percent of included trials assessed at high risk of bias, leading the authors to conclude that exercise may be effective but some uncertainty remains. That is what a cautiously positive finding looks like in this field. The magnesium literature does not currently reach it. Menopause and hot flashes: the study that gets cited, and the problem with it This section requires more care than the last, because the commonly cited evidence looks stronger than it is for a specific and identifiable reason. The most frequently referenced study is a pilot phase II trial conducted at the Mayo Clinic and published by Park and colleagues in 2011, examining magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Participants took 400 milligrams of magnesium oxide at bedtime, increasing to 400 milligrams twice daily after two weeks if symptoms had not improved. The reported results were substantial: greater than 50 percent decreases in fatigue, distress due to hot flashes, and severity of abnormal sweating. Those are impressive numbers, and they are widely quoted. The trial was a phase II pilot. A subsequent larger randomized controlled trial, conducted as NCCTG N10C2 through the Alliance cooperative group and described as a double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes, found smaller effects than the pilot had suggested. The reason that pattern matters is specific to this symptom. Hot flashes are unusually responsive to placebo, and the evidence for this is direct rather than theoretical. A randomized sham-controlled trial testing acupuncture for menopausal hot flashes found that both the real acupuncture group and the sham group improved equally. The intervention and the convincing imitation of the intervention produced the same result. When a symptom responds that strongly to placebo, an uncontrolled or open-label pilot study will systematically overstate an intervention's effect, and the effect will shrink when a proper placebo control is introduced. That is precisely the pattern observed between the 2011 pilot and the larger controlled follow-up. This is not a criticism of the original researchers, who conducted a pilot study and labelled it as such. It is a criticism of how that pilot gets cited, frequently without the phase II designation and without the subsequent controlled trial that qualified it. It is also worth noting that the British Menopause Society does not currently list magnesium as a first-line treatment for menopausal symptoms. Magnesium L-threonate and menopause: the evidence gap stated by researchers Magnesium L-threonate is increasingly marketed for menopausal symptoms on the strength of its ability to cross the blood-brain barrier more effectively than other forms. The mechanistic argument is reasonable. The evidence specific to menopause is essentially absent, and this can be verified from an unusually direct source: the registration documents for a clinical trial currently investigating exactly this question. That trial registration states that randomized controlled trials involving magnesium L-threonate have only confirmed improvement effects on pain and cognitive function, and that research on its effect on improving overall menopausal symptoms is rare. That is researchers setting up a study to answer a question, stating plainly in their own trial documentation that the question has not yet been answered. Any product currently marketing magnesium L-threonate for menopausal symptoms is making a claim ahead of the evidence its own investigators acknowledge is missing. Cortisol and the stress response Magnesium's involvement in stress response regulation is frequently cited as a reason it should help with perimenopausal anxiety and stress reactivity. A systematic review examining the efficacy of magnesium supplementation for subjective measures of anxiety and stress noted that magnesium status is associated with subjective anxiety, which has led to the proposition that supplementation may attenuate anxiety symptoms. The review's assessment of the underlying literature was that the quality of some of the reviewed studies was questionable, and that well-designed randomized controlled trials are needed. Note the structure of that association claim as well. Magnesium status being associated with anxiety is an observational finding, and it runs in both directions: low magnesium could contribute to anxiety, or chronic stress could deplete magnesium, or an unmeasured third factor could drive both. Observational association does not establish that supplementing will reverse the relationship. Where the evidence is genuinely better There is one area where magnesium's evidence in this population holds up reasonably well, and it is worth identifying precisely because the rest of this post has been negative. Sleep. Around 60 percent of women in perimenopause and menopause report sleep disturbance according to NICE guidance, making it the most common complaint in this population. A randomized controlled trial published in the Journal of Research in Medical Sciences found that older adults taking 500 milligrams of magnesium daily for eight weeks fell asleep faster, slept longer, and showed higher melatonin levels compared to placebo. We have covered magnesium and sleep in detail elsewhere, including its limitations, and will not repeat that here. What is worth adding in this specific context is a distinction that usually gets collapsed. The sleep evidence is not hormone-specific. The trial above was conducted in older adults, not specifically in menopausal women, and the mechanism proposed, involving GABA activation and general nervous system calming, is not a hormonal mechanism. If magnesium improves sleep in perimenopausal women, the most likely explanation is that it improves sleep in people generally, and perimenopausal women are people who frequently have disrupted sleep. That is still useful. Sleep disruption is the dominant complaint in this population, and improving it would matter regardless of the mechanism. But it is a different claim than magnesium addressing hormonal change, and conflating the two makes the evidence look broader than it is. It is also worth noting the plausible indirect pathway: if magnesium improves sleep, and poor sleep worsens mood, stress reactivity, and the subjective burden of other symptoms, then downstream improvements could follow without magnesium acting on hormonal pathways at all. Several sources describing women's experience note that those who report hot flash improvement typically notice it alongside better sleep and reduced anxiety, which is consistent with a general nervous system effect rather than a direct hormonal one. What this adds up to The honest hierarchy for magnesium in the context of hormonal change looks like this. For sleep, the evidence is reasonable, the mechanism is plausible, and the relevance to this population is high given how common sleep disruption is. This is the strongest case and it is not a hormonal claim. For premenstrual psychological symptoms, a 2025 systematic review of randomized controlled trials found insufficient evidence for magnesium specifically, with one crossover study suggesting a magnesium and B6 combination may outperform either nutrient alone in a small sample. For hot flashes, the widely cited positive finding came from a phase II pilot, a larger placebo-controlled trial found smaller effects, and the symptom in question is documented to respond strongly to placebo, which explains the discrepancy. For cortisol and stress reactivity, the mechanistic involvement is real, the observational associations exist, and the intervention literature has been assessed as questionable in quality by the researchers reviewing it. For magnesium L-threonate and menopausal symptoms specifically, the investigators currently studying the question state in their own trial documentation that the research is rare. None of this means magnesium is not worth taking. Adequate magnesium intake matters for reasons well established independently of hormonal considerations, and a meaningful share of adults fall short of recommended intake from diet alone. Correcting a genuine shortfall is a reasonable thing to do. What it means is that the specific claim that magnesium addresses hormonal change is considerably less supported than the volume of marketing around it would suggest, and that the most defensible reason to take it in this context is the least glamorous one: sleep support, which is not a hormonal mechanism, in a population that happens to have a high prevalence of sleep disruption. The honest summary Magnesium participates in pathways relevant to hormonal function. That is mechanism, and mechanism is a hypothesis rather than a finding. The clinical evidence, examined directly: insufficient for premenstrual psychological symptoms according to a 2025 systematic review naming magnesium specifically. Promising in a phase II pilot for hot flashes, smaller in the larger controlled follow-up, in a symptom documented to respond strongly to placebo. Questionable in quality for anxiety and stress according to the review assessing it. Explicitly rare for magnesium L-threonate and menopausal symptoms according to researchers currently studying it. Reasonable for sleep, which is not a hormonal mechanism but is the most common complaint in this population. That is a narrower and less satisfying answer than the confident version circulating in this category. It is the one the published trials support, and it is the one worth making decisions on.
Learn more